Tiopronin is considered an antiurolithic agent. It undergoes thioldisulfide exchange with cystine (cysteine-cysteine disulfide) to form tiopronin-cystine disulfide. This complex is more water-soluble and is readily excreted thereby preventing cystine calculi from forming.
While most veterinarians use gentamicin or amikacin and there are no approved veterinary tobramycin products in the U.S., tobramycin can be useful clinically to treat serious gram-negative infections in most species. It is often used in settings where gentamicin-resistant bacteria are a clinical problem. The inherent toxicity of the aminoglycosides limit their systemic use to serious infections when there is either a documented lack of susceptibility to other less toxic antibiotics or when the clinical situation dictates immediate treatment of a presumed gram-negative infection before culture and susceptibility results are reported. Whether tobramycin is less nephrotoxic than either gentamicin or amikacin when used clinically is controversial. Laboratory studies indicate that in a controlled setting in laboratory animals, it may indeed be so.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
犬用公開證據支持專科、組合式與監測式的標籤外使用，但 API 尚不能同時鎖定實體產品、確診、結石與阻塞狀態、尿液目標、蛋白尿及法域。貓只有單一不耐受病例，不能建立通用劑量；29 張數值卡全部不可執行。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。